Filament Health (FH.NE) to release their unaudited financial results for the second quarter of 2021, a period that ended June 30, 2021. As of June 30, Filament had $7.8…
Psychedelics
Filament Health (FH.NE) is developing a pipeline of natural psychedelics products to treat mental health problems like depression and anxiety. August 3, 2021, FH received a patent for the…
In this episode, we take a look at a company that’s on a mission to get safe, natural psychedelics into the hands of everyone who needs them, as soon…
Welcome to Equity.Guru’s Roundtable where our writers weigh in on the pros and cons of a spotlight company, break out where they see value, and help you avoid public…
Researching Filament Health (FH.NE) taught me a lot about the psychedelic space and shroom stocks. As someone who is big on eating clean and organic food, it came to…
For the vast majority of the history of human use of psychedelics, they have been seen as something sacred, a gift from God or mother nature herself. Ayahuasca, which…
Core One Labs (COOL.C) announced that their wholly-owned subsidiaries, Rejuva Mental Health Clinic and Bluejay Mental Health Group, have partnered to assist their patient with completing an application for…
Nova Mentis Life Science (NOVA.C) announced it has filed for orphan drug designation with the European Medicines Agency (EMA) for its propriety psilocybin drug to help treat patients with fragile…
Revive Therapeutics (RVV.C) provided an update on their psychedelics development and clinical programs focused on psilocybin, which they are aiming to use to treat a number of disorders. Revive…
Core One Labs’ (COOL.C) wholly-owned subsidiary Akome Biotech announced they are initiating the next step of their clinical development of their patent-pending psychedelic formulations AKO001 and AKO003. The next…